In NPM1-mutated acute myeloid leukemia, MRD Correlates with Allo-Transplant Benefit.

Published Date: 15 Dec 2023

MRD-negative patients, regardless of FLT3 ITD, do not benefit in the first remission following induction.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An inoperable locally advanced NSCLC trial dubbed "Practice Changing".

2.

Study finds 1 in 12 patients labeled as having 'benign' results actually had high-risk prostate cancer

3.

Biomarker panel offers hope for early pancreatic cancer detection

4.

For patients with clear cell renal cell carcinoma, a new PET agent allows for same-day imaging.

5.

In leukemia, allogeneic HCT is beneficial following primary induction failure.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot